methylphenidate and semaglutide GLP-1 receptor agonist reduces appetite while increasing dopamine reward signaling Semaglutide | DirectMeds
Description
It's a decision made with your provider based on how your treatment is going
Clients often report reduced cravings and a lower overall appetite, empowering them to achieve and maintain their desired weight
For multi-dose protocols, this is the only practical choice
Gastrointestinal symptom profile: The most commonly reported adverse effects directly relate to delayed gastric motility
Having your documented weight history and previous treatment failures ready makes this process smoother
Fierce Healthcare article, 9 May 2023: [12] Thomas CE, Mauer EA, Shukla AP, Rathi S, Aronne LJ
